Overview

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, onset of seizure freedom, change in cognitive function, use of rescue medication and to assess safety and tolerability.

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab